(19)
(11) EP 4 680 752 A1

(12)

(43) Date of publication:
21.01.2026 Bulletin 2026/04

(21) Application number: 24713392.9

(22) Date of filing: 13.03.2024
(51) International Patent Classification (IPC): 
C12N 15/86(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 15/86; C12N 2750/14143; C12N 2830/34; C12N 2740/16043; C12N 2830/008; A61K 48/005; A61K 48/0058
(86) International application number:
PCT/EP2024/056694
(87) International publication number:
WO 2024/189094 (19.09.2024 Gazette 2024/38)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 14.03.2023 US 202363490094 P

(71) Applicant: UCB Biopharma SRL
1070 Brussels (BE)

(72) Inventors:
  • DOWNEY, Patrick Mark
    1070 Brussels (BE)
  • SHRIVASTAVA, Amulya Nidhi
    1070 Brussels (BE)
  • XU, Li
    1070 Brussels (BE)

(74) Representative: UCB Intellectual Property 
c/o UCB IPD 208 Bath Road
Slough, Berkshire SL1 3WE
Slough, Berkshire SL1 3WE (GB)

   


(54) GENE THERAPY